Biomarin Pharmaceutical Inc (BMRN)
66.00
-0.60
(-0.90%)
USD |
NASDAQ |
Nov 04, 16:00
66.78
+0.78
(+1.18%)
After-Hours: 06:33
Biomarin Pharmaceutical Cash from Operations (Quarterly): 221.48M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 221.48M |
| June 30, 2024 | 118.76M |
| March 31, 2024 | 46.97M |
| December 31, 2023 | 27.48M |
| September 30, 2023 | 135.65M |
| June 30, 2023 | 70.06M |
| March 31, 2023 | -73.93M |
| December 31, 2022 | 6.786M |
| September 30, 2022 | 158.32M |
| June 30, 2022 | 56.23M |
| March 31, 2022 | -45.43M |
| December 31, 2021 | 11.18M |
| September 30, 2021 | 97.06M |
| June 30, 2021 | 82.78M |
| March 31, 2021 | 113.51M |
| December 31, 2020 | -13.38M |
| September 30, 2020 | 86.21M |
| June 30, 2020 | 27.74M |
| March 31, 2020 | -15.19M |
| December 31, 2019 | 57.34M |
| September 30, 2019 | 70.12M |
| June 30, 2019 | -24.34M |
| March 31, 2019 | -54.87M |
| December 31, 2018 | 49.37M |
| September 30, 2018 | 47.20M |
| Date | Value |
|---|---|
| June 30, 2018 | -33.86M |
| March 31, 2018 | -42.51M |
| December 31, 2017 | 14.61M |
| September 30, 2017 | 38.29M |
| June 30, 2017 | 18.78M |
| March 31, 2017 | -80.44M |
| December 31, 2016 | -0.21M |
| September 30, 2016 | -10.37M |
| June 30, 2016 | -45.80M |
| March 31, 2016 | -171.45M |
| December 31, 2015 | -65.85M |
| September 30, 2015 | -2.85M |
| June 30, 2015 | -12.99M |
| March 31, 2015 | -137.81M |
| December 31, 2014 | -23.91M |
| September 30, 2014 | -8.557M |
| June 30, 2014 | -11.46M |
| March 31, 2014 | -26.49M |
| December 31, 2013 | -8.997M |
| September 30, 2013 | -9.492M |
| June 30, 2013 | -6.817M |
| March 31, 2013 | -32.03M |
| December 31, 2012 | 11.99M |
| September 30, 2012 | 14.21M |
| June 30, 2012 | -1.42M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-73.93M
Minimum
Mar 2023
221.48M
Maximum
Sep 2024
58.48M
Average
56.78M
Median
Cash from Operations (Quarterly) Benchmarks
| Merck & Co Inc | 5.637B |
| Bristol-Myers Squibb Co | 5.591B |
| Alnylam Pharmaceuticals Inc | 43.71M |
| Bioventus Inc | 15.16M |
| Moderna Inc | -1.274B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -16.16M |
| Cash from Financing (Quarterly) | -499.12M |
| Free Cash Flow | 300.88M |
| Free Cash Flow Per Share (Quarterly) | 1.016 |
| Free Cash Flow to Equity (Quarterly) | 694.63M |
| Free Cash Flow to Firm (Quarterly) | 200.30M |
| Free Cash Flow Yield | 2.32% |